Biomarin Pharma (NASDAQ:BMRN) reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Biomarin Pharma announced earnings per share of $0.08 on revenue of $454.4M. Analysts polled by anticipated EPS of $-0.04 on revenue of $459.19M. That with comparison to EPS of $-0.03 on revenue of $353.2M in the same period a year before. Biomarin Pharma had reported EPS of $0.3 on revenue of $461.1M in the previous quarter. Analysts are expecting EPS of $0.01 and revenue of $472.76M in the upcoming quarter.
Biomarin Pharma shares are up 8.11% from the beginning of the year , still down 4.98% from its 52 week high of $96.20 set on March 4, 2019. They are outperforming the Nasdaq which is down 0.65% year to date.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by Merck&Co on February 5, who reported EPS of $1.16 on revenue of $11.87B, compared to forecasts EPS of $1.15 on revenue of $11.98B.
Novartis ADR had beat expectations on January 29 with fourth quarter EPS of $1.32 on revenue of $12.4B, compared to forecast for EPS of $1.31 on revenue of $12.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting 's earnings calendar
